Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2012 by University of California, San Francisco.
Recruitment status was  Available
Sponsor:
Information provided by (Responsible Party):
University of California, San Francisco
ClinicalTrials.gov Identifier:
NCT00508963
First received: July 27, 2007
Last updated: July 17, 2012
Last verified: July 2012

July 27, 2007
July 17, 2012
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00508963 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis
Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis

Patients with biopsy proven new world cutaneous or mucocutaneous leishmaniasis will be treated with sodium stibogluconate (Pentostam).

Not Provided
Expanded Access
Not Provided
Not Provided
  • Leishmaniasis, Cutaneous
  • Leishmaniasis, Mucocutaneous
Drug: sodium stibogluconate (Pentostam)
20 mg/kg IV every day for 20 or 28 days
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Available
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • Biopsy proven new world cutaneous or mucocutaneous leishmania

Exclusion Criteria:

  • Prolonged QT
  • Liver disease
  • Pancreatitis
Both
18 Years and older
Not Provided
Contact: Jane E Koehler, MA, MD 415-476-3536 jkoehler@medicine.ucsf.edu
United States
 
NCT00508963
UCSF Infectious Diseases
Not Provided
University of California, San Francisco
University of California, San Francisco
Not Provided
Principal Investigator: Brian Schwartz, MD University of CA at San Francisco
Principal Investigator: Kanade Shinkai, MD University of CA at San Francisco
University of California, San Francisco
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP